The Single Use Bioreactor Market is estimated to be valued at USD 3.51 Billion in 2024 and is expected to reach USD 11.2 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 18% from 2024 to 2031.
Figure 1. Single-Use Bioreactor Market Share (%), By Region, 2024
The single-use bioreactor market has been gaining traction over the past few years owing to its advantages over conventional stainless-steel bioreactors. Single-use bioreactors use disposable flexible bags instead of stainless-steel containers for cell culture processes. They provide benefits such as reducing the risks of cross-contamination, minimized clean-in-place and sterilization cycles, and lower capital costs. With rising demand for biologics in the biopharmaceutical industry, more manufacturers are adopting single-use technologies to accelerate production cycles and facilitate flexible operations during drug development and manufacturing processes. Advances in single-use sensor technologies and analytics are further enhancing the efficiency and control in cell culture processes. This is expected to drive continued adoption of single-use bioreactors in the coming years.
Market Dynamics:
The global single-use bioreactor market is witnessing strong growth driven by several factors. Rising demand for biologics and growing preference of biopharmaceutical manufacturers for single-use systems to prevent contamination risks and enable greater flexibility are major growth drivers. Additionally, low costs of setup and operation, minimized validation requirements, and faster implementation compared to stainless steel bioreactors have boosted the appeal of single-use bioreactors. However, concerns regarding extractable and leachable substances from bags pose a challenge. Meanwhile, technology advancements in sensor technologies, analytics, and control systems integrated with single-use bioreactors are expected to present lucrative opportunities for market expansion.
Key Features of the Study:
- his report provides in-depth analysis of the global single-use bioreactor market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global single-use bioreactor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Sartorius Stedim Biotech, Thermo Fisher Scientific, GE Healthcare, Danaher, and Merck Millipore
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global single-use bioreactor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global single-use bioreactor market
Detailed Segmentation-
- By Product
- Single-use Bioreactor Systems
- Media Bags
- Filtration Assemblies
- Other Products
- By Cell Type
- Mammalian Cell
- Bacteria
- Yeast
- Other Cell Types
- By Molecule Type
- Vaccines
- Monoclonal Antibodies
- Stem Cells
- Recombinant Proteins
- Other Molecule Types
- By End User
- Pharmaceutical and Biopharmaceutical Industries
- Contract Research Organizations (CRO)
- Academic & Research Institutes
- Other End Users
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Sartorius Stedim Biotech
- Thermo Fisher Scientific
- Danaher
- Merck KgaA
- Celltainer Biotech BV
- Getinge AB
- Eppendorf AG
- Cellexus
- PBS Biotech Inc.
- Distek Inc.
- ABEC
- Able Corporation & Biott Corporation
- G&G Technologies Inc.
- Solida Biotech GmbH
- Satake Chemical Equipment Mfg., Ltd.
- Stobbe Pharma GmbH
- bbi-biotech GmbH